Demographics, Prior Therapies, and Reasons for Cemiplimab Treatment: Prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) Study in Patients with Advanced Cutaneous Squamous Cell Carcinoma

Main Article Content

Guilherme Rabinowits
Jade Homsi
Mina Nikanjam
Rhonda Gentry
John Strasswimmer
Suraj Venna
Michael Migden
Sunandana Chandra
Emily Ruiz
Haixin Zhang
Jennifer McGinniss
Alex Seluzhytsky
Jigar Desai

Keywords

Skin Cancer, Squamous Cell Carcinoma, Biologic, Cemiplimab, Demographics

Abstract

Abstract not available.

References

1. Rogers HW et al. JAMA Dermatol. 2015;151:1081–1086.

2. Leiter U et al. J Invest Dermatol. 2017;137:1860–1867.

3. Jennings L and Schmults CD. J Clin Aesthet Dermatol. 2010;3:39–48.

4. Migden MR et al. N Engl J Med. 2018;379:341–351.

5. Schmults CD et al. JAMA Dermatol. 2013;149:541–547.

6. Weinberg AS et al. Dermatol Surg. 2007;33:885–899.

7. Burova E et al. Mol Cancer Ther. 2017;16:861–870.

8. Migden MR et al. J Clin Oncol. 2019;37:6015–6015.

9. Rischin D et al. J Immunother Cancer. 2020;8:e000775.

10. Regeneron Pharmaceuticals, Inc. LIBTAYO® [cemiplimab-rwlc] injection full US prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/
761097s000lbl.pdf. Accessed July 13, 2020.

11. European Medicines Agency. Libtayo: EPAR - product information. Available from: https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf. Accessed August 24, 2020.